NCT00331500View on ClinicalTrials.gov

Olopatadine 0.2% for the Treatment of Allergic Conjunctivitis

PHASE3CompletedINTERVENTIONAL
Enrollment

287

Participants

Timeline

Start Date

April 18, 2006

Primary Completion Date

July 27, 2006

Study Completion Date

July 27, 2006

Conditions
Allergic Conjunctivitis
Interventions
DRUG

Olopatadine Hydrochloride Ophthalmic Solution, 0.2%

DRUG

Olopatadine Hydrochloride Ophthalmic Solution Vehicle

Inactive ingredients used as a placebo comparator

Sponsors

Lead Sponsor

Alcon Research
All Listed Sponsors
lead

Alcon Research

INDUSTRY